Indivior Pharmaceuticals (INDV) Invested Capital (2021 - 2026)

Indivior Pharmaceuticals' Invested Capital history runs 6 years deep, the most recent figure standing at -$144.0 million for Q1 2026.

• In Q1 2026, Invested Capital rose 46.07% year-over-year to -$144.0 million; the TTM figure through Mar 2026 stood at -$144.0 million (up 46.07% YoY), while the FY2025 annual figure was -$69.0 million, down 1625.0% from the prior year.
• Invested Capital was -$144.0 million for Q1 2026 at Indivior Pharmaceuticals, down from -$69.0 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $309.0 million in Q4 2022 to a low of -$310.0 million in Q3 2024.
• Historically, Invested Capital has averaged -$118.1 million across 5 years, with a median of -$161.0 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Invested Capital plunged 1625.0% in 2025, then soared 46.07% in 2026.
• A 5-year view of Invested Capital shows it stood at $309.0 million in 2022, then sank by 81.88% to $56.0 million in 2023, then tumbled by 107.14% to -$4.0 million in 2024, then slumped by 1625.0% to -$69.0 million in 2025, then sank by 108.7% to -$144.0 million in 2026.
• The last three Invested Capital figures came in at -$144.0 million (Q1 2026), -$69.0 million (Q4 2025), and -$189.0 million (Q3 2025), per Business Quant data.